<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03776175</url>
  </required_header>
  <id_info>
    <org_study_id>C3711001</org_study_id>
    <nct_id>NCT03776175</nct_id>
  </id_info>
  <brief_title>A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.</brief_title>
  <official_title>A PHASE 2A, RANDOMIZED, DOUBLE BLIND (SPONSOR-OPEN), PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF PF-05221304 AND PF-06865571 CO-ADMINISTERED FOR 6 WEEKS IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the effect of PF 05221304 alone, PF 06865571 alone, the co
      administration of PF 05221304 and PF 06865571, or placebo on whole liver fat in subjects with
      NAFLD. In addition, this study will evaluate the safety and tolerability of co administration
      of PF 05221304 and PF 06865571 along with the effects on selected pharmacodynamics
      (PD)/exploratory parameters, compared to administration of PF 05221304 alone, PF 06865571
      alone, and placebo in adults with NAFLD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2019</start_date>
  <completion_date type="Actual">October 11, 2019</completion_date>
  <primary_completion_date type="Actual">September 9, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative change in whole liver fat as assessed by magnetic resonance imaging proton density fat fraction (MRI‑PDFF).</measure>
    <time_frame>Baseline up to Day 42</time_frame>
    <description>Mean relative changes between placebo and each active drug arm (PF‑05221304 monotherapy, PF‑06865571 monotherapy and PF‑05221304 plus PF‑06865571 combination) will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to 14 Days after last dose</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline up to 14 Days after last dose</time_frame>
    <description>Clinically significant ECG findings included: QT interval, heart rate, QTcF interval, PR interval, and QRS interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Change From Baseline in Vital Signs</measure>
    <time_frame>Baseline up to 14 Days after last dose</time_frame>
    <description>Changes from baseline in systolic blood pressure, diastolic blood pressure and pulse rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities</measure>
    <time_frame>Baseline up to 14 Days after last dose</time_frame>
    <description>Laboratory parameters included: hematology, chemistry, and urinalysis Clinical significance of laboratory parameters was determined at the investigator's discretion.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease (NAFLD)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (PF 05221304) BID Placebo (PF 06865571) BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05221304 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg PF-05221304 BID Placebo (PF-06865571) BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06865571 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (PF-05221304) BID 300 mg PF-06865571 BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05221304 and PF-06865571 Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg PF-05221304 BID 300 mg PF-06865571 BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05221304 Monotherapy</intervention_name>
    <description>Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of Placebo for PF-06865571, each to be taken twice daily for 41 days and once on Day 42.</description>
    <arm_group_label>PF-05221304 Monotherapy</arm_group_label>
    <arm_group_label>PF-05221304 and PF-06865571 Combination</arm_group_label>
    <other_name>Arm B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06865571 Monotherapy</intervention_name>
    <description>Participants enrolled in this Arm will receive 300 mg dose of PF-06865571 (3 tablets of 100 mg each) and 3 tablets of Placebo for PF-05221304, all to be taken twice daily for 41 days and once on Day 42.</description>
    <arm_group_label>PF-05221304 and PF-06865571 Combination</arm_group_label>
    <arm_group_label>PF-06865571 Monotherapy</arm_group_label>
    <other_name>Arm C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.</description>
    <arm_group_label>PF-05221304 Monotherapy</arm_group_label>
    <arm_group_label>PF-06865571 Monotherapy</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Arm A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05221304 and PF-06865571 Combination</intervention_name>
    <description>Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of PF-06865571 (3 tablets of 100 mg each), each to be taken twice daily for 41 days and once on Day 42.</description>
    <arm_group_label>PF-05221304 and PF-06865571 Combination</arm_group_label>
    <other_name>Arm D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects or female subjects of non childbearing potential

          -  Total body weight of &gt;50 kg (110 lbs) and a BMI greater than or equal to 25 kg/m2

          -  Medical diagnosis of Type 2 Diabetes Mellitus (T2DM) being treated with no more than 1
             acceptable oral antidiabetic drug OR Subjects without a diagnosis of T2DM that meet 2
             or more of the following 5 criteria commonly associated with metabolic syndrome

               -  Fasting Plasma Glucose (FPG) greater than or equal to 100 mg/dL;

               -  Documentation of at least stage 1 hypertension or medical history of
                  hypertension;

               -  Fasting serum HDL C &lt;40 mg/dL for males and &lt;50 mg/dL for females, or on
                  pharmacological agents with explicit purpose to increase HDL-C;

               -  Fasting serum triglyceride (TG) greater than or equal to 150 mg/dL or on
                  pharmacological agents with explicit purpose to decrease TG;

               -  Waist circumference greater than or equal to 40 inches (102 cm) for males and 35
                  inches (89 cm) for females.

          -  Liver fat greater than or equal to 8% measured by MRI PDFF

        Exclusion Criteria:

          -  Subjects with acute or chronic medical or psychiatric condition.

          -  Subjects with any of the following clinical laboratory abnormalities:

               -  Fasting TG &gt;400 mg/dL;

               -  AST, ALT, or GGT &gt;2.0x ULN;

               -  Hemoglobin A1c (HbA1c) &gt;7.0%;

               -  Fasting plasma glucose &gt;270 mg/dL;

               -  Total bilirubin &gt;1.5x ULN;

               -  Albumin &lt; lower limit of normal (LLN);

               -  Platelet count &lt;0.95x LLN;

               -  International normalized ratio (INR) greater than or equal to 1.3.

          -  A positive urine test for illicit drugs.

          -  History of regular alcohol consumption.

          -  Seated systolic BP&gt;=160 mmHg and/or diastolic BP&gt;=100 mmHg.

          -  Supine 12 lead ECG demonstrating a corrected QT (QTcF) interval &gt;450 msec or a QRS
             interval &gt;120 msec.

          -  Subjects with an estimated GFR &lt;60 mL/min/1.73m2.

          -  Evidence or diagnosis of other forms of chronic liver diseases.

          -  Subjects with any of the following medical conditions:

               -  Any condition possibly affecting drug absorption (eg prior bariatric surgery,
                  gastrectomy, ileal resection);

               -  Diagnosis of type 1 diabetes mellitus;

               -  History of congestive heart failure, unstable angina, myocardial infarction,
                  stroke, or transient ischemic attack;

               -  Any malignancy not considered cured (except basal cell carcinoma and squamous
                  cell carcinoma of the skin);

               -  Active placement of medical devices in/on thoracic or abdominal cavities such as
                  pacemakers, defibrillators;

          -  Subjects with any anatomical or pathological abnormality that would either preclude or
             tend to confound the analysis of study data.

          -  Blood donation of approximately 1 pint or more within 60 days prior to dosing.

          -  Subjects taking prohibited concomitant medication(s) or those unwilling/unable to
             switch to permitted concomitant medication(s)

          -  Weight loss of greater than or equal to 5% within 1 month prior to Screening.

          -  Unwilling or unable to comply with the Lifestyle Requirements criteria of the
             protocol.

          -  Pregnant female subjects; breastfeeding female subjects; female subjects of
             childbearing potential; fertile male subjects who are unwilling or unable to use
             highly effective method(s) of contraception.

          -  Investigator site staff members or Pfizer employees, including their family members,
             directly involved in the conduct of the study.

          -  Subjects with known prior treatment with or participation in a clinical trial
             involving any of the IPs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Franco Felizarta, Md</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Medical Associates of Los Angeles</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProSciento, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Wilshire</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute, LLC</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Floridian Clinical Research, LLC</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Centers of America, LLC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmax Research Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Maitland</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Gastroenterology Associates, LLC</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS-MRA, LLC-Main Office</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East-West Medical Research Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L-MARC Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clarity Clinical Research</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Point Clinical Trials Center</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3 Wake Research, Inc</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Gastroenterology</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group - Mt. Auburn</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Horizons Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WR-Clinsearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center - Radiology</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research-Richmond, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3711001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 12, 2018</study_first_submitted>
  <study_first_submitted_qc>December 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2018</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

